Hi, everyone. Let's get started. Welcome to the 44th Annual JPMorgan Healthcare Conference. My name is Priyanka Grover, and I'm part of the JPMorgan Biotech team. Today, our next presenting company is ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recent discussions on X about Recursion Pharmaceuticals (RXRX) have centered around the company's notable stock price surge of 14% over the past month, a performance that stands out against a ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Automaker Stellantis and Massachusetts-based battery startup Factorial Energy have announced validation of a new solid-state electric vehicle battery that could be a game-changer for the industry.

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...

I'm diving deep into the intersection of infrastructure and machine learning. I'm fascinated by exploring scalable architectures, MLOps, and the latest advancements in AI-driven systems ...